Clinical trials: Carbapenem-Resistant Enterobacteriaceae
Carbapenem-Resistant Enterobacteriaceae, Lower Respiratory Tract Infections
Correlation Analysis of Xpert Carba-R Detection of Non-colonized CRE in BALF and Rectal Swabs From Patients With LRTI
Assess the correlation between Xpert Carba-R detection of carbapenemase gene types in bronchoalveolar lavage samples and rectal swab samples from non-colonized CRKP patients with lower respiratory tract infections, and evaluate…
- Trial name
- NCT06636890
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Intestinal Colonization With Multidrug-resistant Bacteria
Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy
This investigator initiated,international, multicenter open-label, randomized controlled trial aims to assess whether a 5 day course of oral nonabsorbable antibiotics (colistin sulfate 2 million IU per os 4x/day and neomycin…
- Trial name
- R-GNOSIS WP3 (NCT02472600)
- Testing
- Colistin, Neomycin, Fecal microbiota transplantation (FMT)
- Where
- 4 sites in France, Israel and 2 more
- Volunteers
- 39 people
- Sponsor
- Stephen Harbarth
Urinary Tract Infection Complicated, Acute Pyelonephritis
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Vabomere™, (meropenem-vaborbactam) is being compared to the Best Available Therapy in the treatment of adults with selected serious infections due to Carbapenem Resistant Enterobacteriaceae
- Conditions
- Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- NCT02168946
- Testing
- Vabomere, Best Available Therapy
- Where
- 50 sites in United States, Argentina and 6 more
- Volunteers
- 77 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Carbapenem-Resistant Enterobacteriaceae Infection
Fecal Microbiota Transplantation for Carbapenem-resistant Enterobacteriaceae
2:1, open-label, single center, randomized controlled trial comparing FMT vs. no intervention for CRE carriers,
- Trial name
- NCT04146337
- Testing
- FMT
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Rambam Health Care Campus
Vancomycin-Resistant Enterococcus, Extended-Spectrum Beta Lactamase-Producing Enterobacteriaceae, or Carbapenem-Resistant Enterobacteriaceae Colonized Subjects
VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms
This randomized, open-label, clinical study aims to explore the safety and tolerability of KB109, a novel glycan, versus an observational control group on the gut microbiome in subjects whose gastrointestinal tracts are colonized…
- Trial name
- VITORA (NCT03944369)
- Testing
- KB109, No intervention
- Where
- 8 sites in United States
- Volunteers
- 3 people
- Sponsor
- Kaleido Biosciences
Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
Antimicrobial resistance is a major global problem, particularly in hospital-acquired infections (HAIs). Gram-negative bacilli (GNB), including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, are among the…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection, Severe Infection, Pseudomonas Aeruginosa
- Trial name
- OPTIMISE (NCT05210387)
- Testing
- Duration of therapy
- Where
- 29 sites in Brazil
- Volunteers
- 107 people
- Sponsor
- Hospital Moinhos de Vento
Bloodstream Infections, Enterobacteriaceae Infections
ANTIBIOTIC-RESISTANT ENTEROBACTERALES BLOODSTREAM INFECTIONS AND RISK FACTORS IN PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT
In this study, we first aimed to reveal the resistance profile of Enterobacteriales bloodstream infections at our center. We evaluated data from patients with ESBL, colistin, and carbapenem resistance and identified resistance…
- Conditions
- Bloodstream Infections, Enterobacteriaceae Infections, Intensive Care (ICU), Antibiotic Resistant Infection
- Trial name
- NCT07172932
- Where
- Turkey (Türkiye)
- Volunteers
- 314 people
- Sponsor
- Ankara City Hospital Bilkent
Carbapenem-Resistant Enterobacteriaceae, Colonisation
Tackling Resistance And HealthCare Economics Through CPE Screening
The goal of this clinical study is to learn if it is possible to reduce the spread of resistant bacteria called CPEs (Carbapenemase producing Enterobacterales) between patients admitted to hospital.
- Trial name
- TRACE-CPE (NCT07663110)
- Testing
- Rapid molecular diagnostic test for CPE identification
- Where
- 2 sites in United Kingdom
- Volunteers
- 16,000 people
- Sponsor
- Imperial College London
Intestinal Multi-drug Resistant Organism Colonization
Further MT for Antibiotic-Resistant Bacterial Colonization
The purpose of this study is to better understand the effectiveness and safety of microbiome therapies (MT) as a treatment for patients with Multidrug Resistant Organism (MDRO) colonization after an infection.
- Trial name
- FAIR (NCT05835206)
- Testing
- Microbiome Therapeutic
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- Emory University
Urinary Tract Infection, Complicated, Acute Pyelonephritis
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
A multi-center, retrospective study of cases of serious bacterial infections including complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP), Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Acquired…
- Conditions
- Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- NCT02420366
- Where
- 22 sites in United States, Greece and 2 more
- Volunteers
- 257 people
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Hematological Diseases, Carbapenem-resistant Enterobacteriaceae
Carbapenem-resistant Organisms (CRO) Screening From Rectal Swabs in Patients With Hematological Diseases in China
Carbapenem-resistant Organisms (CRO) include Carbapenem-resistant Enterobacteriaceae (CRE), Carbapenem-resistant Pseudomonas aeruginosa (CRPA) and Carbapenem-resistant Acinetobacter baumannii (CRAB).
- Conditions
- Hematological Diseases, Carbapenem-resistant Enterobacteriaceae, Carbapenem-resistant Pseudomonas Aeruginosa, Carbapenem-resistant Acinetobacter Baumannii
- Trial name
- CROSS (NCT05002582)
- Where
- China
- Volunteers
- 5,000 people
- Sponsor
- Sir Run Run Shaw Hospital
Septic Shock
Pentaglobin in CRE and PA Neutropenic Infections
To demonstrate that the early addition of Pentaglobin to the best available antimicrobial therapy is able to reduce mortality and improve survival in neutropenic febrile acute leukemia or allo- Hematopoietic stem cell…
- Trial name
- PENTALLO (NCT03494959)
- Testing
- Pentaglobin
- Where
- 20 sites in Italy
- Volunteers
- 120 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Carbapenem-Resistant Enterobacteriaceae Infection
Drug Resistance Mechanism of Enterobacteriaceae and Its Strategies
The first aim of this study is to explore the drug resistance mechanism of Enterobacteriaceae bacteria and to evaluate the treatment effect of ceftazidime-avibactam (CAZ-AVI) in combination with aztreonam (ATM) against…
- Trial name
- NCT05850871
- Testing
- CAZ/AVI plus Aztreonam, Conventional treatment
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Qianfoshan Hospital
Drug Resistance, Bacterial
Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes.
This study evaluates individual and collective factors of ESBL and CRE carriage in nursing homes.
- Trial name
- R'EHPAD (NCT03248999)
- Testing
- rectal swab
- Where
- France
- Volunteers
- 264 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Carbapenemase-Producing Enterobacteriaceae (CPE), Healthcare-Associated Infections (HAIs)
Effect of Daily Chlorhexidine Bathing and Antibiotic/PPI Stewardship on Prevention of CPE Transmission and Infection
This multicenter, cluster-randomized crossover trial aims to evaluate the effectiveness and safety of a bundled intervention-including daily chlorhexidine bathing and targeted antimicrobial and proton pump inhibitor (PPI)…
- Trial name
- NCT07039955
- Testing
- Daily Chlorhexidine Bathing, Antimicrobial and PPI Stewardship Program, Standard Bathing
- Where
- 3 sites in South Korea
- Volunteers
- 5,760 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Bacteremia
Mortality of MBL-producing Enterobacteriaceae Bacteremias with the Combined Use of Ceftazidime-avibactam and Aztreonam Vs. Other Active Antibiotics. a Multicenter Target Trial Emulation.
Ceftazidime-avibactam and aztreonam combination (CAZAVI + ATM) presents a potential alternative for the treatment of metallo-beta-lactamase (MBL)-type carbapenemase-producing Enterobacteriaceae (CPE) bacteremia, particularly…
- Trial name
- NCT06419296
- Where
- 16 sites in Argentina
- Volunteers
- 265 people
- Sponsor
- Hospital Italiano de Buenos Aires
Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae
Rectal Carriage of Carbapenemase Producing-Enterobacteriaceae on Admission to a French University Teaching Hospital
"The emergence and spread of highly resistant bacteria, including carbapenemase-producing Enterobacteriaceae (CPE), is a public health challenge given their rapid spread and the lack of active antibiotics against these bacteria.
- Trial name
- Prev-CPE (NCT05798351)
- Where
- France
- Volunteers
- 1,195 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Carbapenem-Resistant Enterobacteriaceae Colonization
Fecal Microbiota Transplantation for Decolonization of Multidrug-resistant Microorganisms
The aim of the study is to see whether fecal microbiota transplantation is effective to decolonize multidrug-resistant organisms.
- Trial name
- NCT07265817
- Testing
- Fecal Microbial transplant Capsules
- Volunteers
- 60 people
- Sponsor
- Kyungpook National University Hospital
Carbapenem-Resistant Enterobacteriaceae Infection, KPC
Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections
This is an observation study comparing prospective use of Imipenem/Cilastatin/Relebactam (IMI/REL) to retrospective data using Meropenem/Vabobactam (MVB)and Ceftazidime/Avibactam CZA) in treatment of Klebsiella Producing…
- Conditions
- Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections, Antibiotic Resistant Infection
- Trial name
- NCT04785924
- Testing
- Imipenem+Relebactam
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Enterobacteriaceae Infections, Multi-antibiotic Resistance
FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae
Antibiotic resistance (AR) is a critical public health threat and one of the greatest challenges of the 21st century. In an estimate of 2019, nearly 700.000 infections and 33.000 attributable deaths from multi-drug-resistant…
- Trial name
- FMT_CRE (NCT05791396)
- Testing
- Donor - FMT
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS